262 related articles for article (PubMed ID: 16860917)
1. Toxicophores: investigations in drug safety.
Williams DP
Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
[TBL] [Abstract][Full Text] [Related]
2. Selection of new chemical entities with decreased potential for adverse drug reactions.
Park KB; Dalton-Brown E; Hirst C; Williams DP
Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
[TBL] [Abstract][Full Text] [Related]
3. Role of reactive metabolites in drug-induced hepatotoxicity.
Srivastava A; Maggs JL; Antoine DJ; Williams DP; Smith DA; Park BK
Handb Exp Pharmacol; 2010; (196):165-94. PubMed ID: 20020263
[TBL] [Abstract][Full Text] [Related]
4. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
Williams DP; Park BK
Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activation in drug-induced liver injury.
Leung L; Kalgutkar AS; Obach RS
Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
[TBL] [Abstract][Full Text] [Related]
6. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
Tang W; Lu AY
Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
[TBL] [Abstract][Full Text] [Related]
7. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
[TBL] [Abstract][Full Text] [Related]
8. The role of metabolic activation in drug-induced hepatotoxicity.
Park BK; Kitteringham NR; Maggs JL; Pirmohamed M; Williams DP
Annu Rev Pharmacol Toxicol; 2005; 45():177-202. PubMed ID: 15822174
[TBL] [Abstract][Full Text] [Related]
9. Reactive metabolites as a cause of hepatotoxicity.
Prescott LF
Int J Clin Pharmacol Res; 1983; 3(6):437-41. PubMed ID: 6381340
[TBL] [Abstract][Full Text] [Related]
10. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science.
Antoine DJ; Williams DP; Park BK
Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1415-27. PubMed ID: 18950283
[TBL] [Abstract][Full Text] [Related]
11. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.
Tang W
Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):407-20. PubMed ID: 17539747
[TBL] [Abstract][Full Text] [Related]
12. The role of reactive drug metabolites in immune-mediated adverse drug reactions.
Hess DA; Rieder MJ
Ann Pharmacother; 1997 Nov; 31(11):1378-87. PubMed ID: 9391694
[TBL] [Abstract][Full Text] [Related]
13. [Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
Pessayre D; Benhamou JP
C R Seances Soc Biol Fil; 1979; 173(2):458-68. PubMed ID: 159767
[TBL] [Abstract][Full Text] [Related]
14. Are chemically reactive metabolites responsible for adverse reactions to drugs?
Williams DP; Kitteringham NR; Naisbitt DJ; Pirmohamed M; Smith DA; Park BK
Curr Drug Metab; 2002 Aug; 3(4):351-66. PubMed ID: 12093355
[TBL] [Abstract][Full Text] [Related]
15. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity.
Park BK; Laverty H; Srivastava A; Antoine DJ; Naisbitt D; Williams DP
Chem Biol Interact; 2011 Jun; 192(1-2):30-6. PubMed ID: 20846520
[TBL] [Abstract][Full Text] [Related]
16. Investigation of toxic metabolites during drug development.
Park K; Williams DP; Naisbitt DJ; Kitteringham NR; Pirmohamed M
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):425-34. PubMed ID: 15996699
[TBL] [Abstract][Full Text] [Related]
17. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
Grillo MP
Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
[TBL] [Abstract][Full Text] [Related]
18. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
Zhou S; Chan E; Duan W; Huang M; Chen YZ
Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.
Giri S; Nieber K; Bader A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107
[TBL] [Abstract][Full Text] [Related]
20. Bioactivation and bound residues.
Burgat-Sacaze V; Rico A; Delatour P
Food Addit Contam; 1984; 1(2):121-9. PubMed ID: 6536524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
